iCo Therapeutics redefines and in-licenses existing drug candidates by employing reformulation and delivery technologies for new or expanded use indications. The company has exclusive worldwide rights to two drug candidates: iCo-007 for diabetic macular edema and iCo-008 for other sight-threatening diseases. The company also has exclusive worldwide rights to an oral drug delivery platform which uses a known anti-fungal drug to treat life-threatening infectious diseases. For more information, visit the company’s website at www.icotherapeutics.com.